Saturday, July 11, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
MARKETSFTC Forces John Deere to Open Its Repair Ecosystem — and the Aftermarket Parts Industry WinstodayENERGYOccidental's Carbon Capture Isn't a Climate Bet. It's a Tax Credit Trade.4 weeks agoTRADE & TARIFFSTariff Tailwinds Are Still Running for U.S. Metals — but the Easy Money in Steel and Aluminum May Already Be PricedtodayTECHThe Federal Data Center Mandate: How Washington's AI Spending Flows to Hardware4 weeks agoTRADE & TARIFFSMcCormick's $28M Tariff Refund Is a One-Time Cushion — the Underlying Cost Pressure Hasn't Gone AwaytodayTECHThe Domestic Equipment Play: How Foreign Chip Tool Restrictions Hand Applied Materials a Structural Edge4 weeks agoENERGYCommonwealth LNG Permit Review Opens — Another Export Terminal in the Queue Benefits the Whole LNG Supply ChaintodayENERGYSLB's Quiet Second Act: How Sanctions Reroute the Oilfield Services Backlog4 weeks agoTECHTrump Accelerates Post-Quantum Encryption Deadlines — and a Handful of Small-Cap Security Firms Are the Direct BeneficiariestodayTECHThe AI Diffusion Rule Is Picking Winners Inside the Chip Stack — and It Is Not Who You Think4 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts Years Off the SMR TimelinetodayENERGYThe FERC Docket Nobody Reads: How Pipeline Certificates Quietly Pick LNG's Winners4 weeks agoDEFENSENATO's 3.5% GDP Spending Push Is a Multi-Year Order Book for U.S. Defense PrimestodayTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron4 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable MarkettodayTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map4 weeks agoHEALTHCARE & FDAMedicare Starts Covering Obesity Drugs — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential CustomerstodayENERGYWhy Williams (WMB) Is Really a Policy Stock, Not a Pipeline Stock4 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger MarketyesterdayENERGYDOE Reopens the LNG Export Spigot: Cheniere Cashes In First, Kinder Morgan Collects the Toll4 weeks agoHEALTHCARE & FDAElevance Suing CMS Over Medicare Advantage Stars Is a Warning Sign for the Entire Managed Care SectoryesterdayTECHThe Chip Stack Below the Pentagon's AI Buildup4 weeks agoTECHWhite House Quantum Summit and Accelerated PQC Deadlines Create a Spending Runway for IonQ and IBMyesterdayDEFENSEHII's Mission Technologies: The Unsexy Segment Where Navy Autonomy Dollars Actually Land First4 weeks agoENERGYCommonwealth LNG Permit Review Opens a New Export Capacity Race — Cheniere Holds the Pole PositionyesterdayTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion4 weeks agoCRYPTOSEC's Pending Crypto Safe Harbor Rule Is the Clearest Regulatory Tailwind Coinbase Has Seen in YearsyesterdayDEFENSEThe Refueling Line Nobody Prices Into BWXT4 weeks agoDEFENSENATO's 3.5% GDP Spending Push Sends a Long-Term Revenue Signal to Raytheon, Lockheed, and NorthropyesterdayDEFENSEThe Law That Guarantees Matson a Buyer, No Matter the Price4 weeks agoHEALTHCARE & FDAMedicare Covering Obesity Drugs for the First Time Is a Direct Volume Catalyst for Novo Nordisk and Eli LillyyesterdayENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers4 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program as State-Level Momentum Builds — Constellation, Vistra, and Oklo Are the Plays4 days agoTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two4 weeks agoENERGYU.S.-Iran Initial Deal Eases Sanctions Pressure — Oil Prices Face a Ceiling, E&P Stocks Feel It4 days agoDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat4 weeks agoDEFENSENATO's 'Report Card' Pressure Means Years of European Defense Spending — RTX and Lockheed Are the First Calls4 days agoENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom4 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Obesity Drugs — Novo Nordisk and Eli Lilly Are the Direct Winners4 days agoDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch4 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Market4 days agoDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes3 weeks agoCRYPTOSEC Commissioner Signals Crypto Clarity Act Could Pass This Summer — Coinbase and Robinhood Are the Clearest Beneficiaries4 days agoDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization3 weeks agoTECHWhite House Lifts Export Controls on Anthropic's Advanced AI Models — Nvidia and AMD Are the Coattail Trade4 days agoENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear3 weeks agoDEFENSENATO's Spending Surge Is Real — and the US Defense Primes Are the Ones Getting Paid5 days agoENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Children as Young as 2, Widening the Market for Vertex and CRISPR Therapeutics5 days agoDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop3 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Payday for AeroVironment5 days agoENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade3 weeks agoDEFENSEThe US-Iran Ceasefire Deal Pressures Oil Prices — and Reshuffles the Defense Trade5 days agoDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One3 weeks agoTECHTrump's Quantum Computing Executive Orders Create a Policy Tailwind for a Handful of Public Names5 days agoDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money3 weeks agoCRYPTOCrypto Clarity Act Progress and SEC's ETF Rule Review Are the Two Biggest Near-Term Catalysts for Coinbase and Robinhood5 days agoENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors3 weeks agoTRADE & TARIFFSNike's Tariff Refund Windfall Shows How Import-Heavy Brands Can Turn Trade Policy Into a Margin Story6 days agoENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus3 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program, Adding Momentum to the SMR Buildout Trade6 days agoDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AI3 weeks agoHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Users on Notice — and Creates an Opening for Clean-Label Suppliers6 days agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alive3 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment6 days agoDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Prime3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market6 days agoDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spending3 weeks agoTECHTrump's Post-Quantum Cryptography Executive Order Creates a Compliance Spending Mandate — and Clear Beneficiaries6 days agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hub3 weeks agoHEALTHCARE & FDAMedicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New Payerlast weekDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washington3 weeks agoTECHCommerce Department's AI Model Export Controls Are the Next Nvidia Headwind — and AMD Isn't Immunelast weekENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economics3 weeks agoDEFENSEHegseth's NATO Broadside and European Force Review Put Defense Primes in a Complicated Spotlast weekENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deduction3 weeks agoCRYPTOBitcoin Is Down 33% at Mid-Year and ETF Outflows Hit $4.3B in June — Coinbase and the Miners Are Feeling Itlast weekDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Bet3 weeks agoENERGYWashington Is Rewriting Nuclear Radiation Safety Rules — Constellation, Vistra, and the SMR Crowd All Winlast weekDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratos3 weeks agoENERGYThe US-Iran Initial Deal Puts Sanction Relief on the Table — and That's a Headwind for Oil Prices and E&P Stockslast weekENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keys3 weeks agoWHITE HOUSETrump's Quantum Executive Order Sets a Hard Deadline — and Quantum Computing Stocks Are the Immediate Beneficiarylast weekDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguise3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger Marketlast weekDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Story2 weeks agoTRADE & TARIFFSNike's Tariff Refunds Are a One-Time Boost, Not a Structural Fix — Here's What the Q4 Beat Actually Meanslast weekENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Gift2 weeks agoWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity Stacklast weekENERGYThe BLM Calendar That Moves COP and OXY2 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its Rivalslast weekDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Through2 weeks agoDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's Expenselast weekDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivot2 weeks agoCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most Risklast weekENERGYLNG Export Licenses: How a FERC Approval Mints a Monopoly2 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customerslast weekDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differently2 weeks agoDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending Boomlast weekENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oil2 weeks agoDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets Paidlast weekDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenly2 weeks agoWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet Tailwindlast weekDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes2 weeks agoMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big Techlast weekDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program2 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is Movinglast weekDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Order2 weeks agoTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real Moneylast weekDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machine2 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Marketlast weekDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own Itlast weekDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company Foreverlast weekDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sideslast weekDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stocklast weekDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Streamlast weekTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watchlast weekDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligationlast weekMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Politicallast weekDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTXlast weekTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producerslast weekDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Betlast weekDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spendinglast weekDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Tradelast weekDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Gamelast weekDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risklast week
1 free article left this week. A free account gets you 4 a week.Go Pro →
Healthcare & FDA

FDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable Market

Extending the gene therapy's label down to age 2 opens a new patient pool and resets the revenue ceiling for both companies.

Image: Money Racket
By at Money Racket · Jul 11, 2026

The FDA granted a supplemental approval for Casgevy (exagamglogene autotemcel) in patients as young as 2 years old with sickle cell disease or transfusion-dependent beta thalassemia. Previously, the therapy was only approved for patients 12 and older.

Who cashes in: Vertex Pharmaceuticals (VRTX) and CRISPR Therapeutics (CRSP) co-own Casgevy and split economics on every treatment. Pediatric patients represent a meaningful expansion of the eligible population — sickle cell disease disproportionately affects children, and catching patients earlier in disease progression is exactly the kind of label expansion that moves long-term revenue models. VRTX is the commercial lead and larger of the two; CRSP is the higher-beta play on the same catalyst. Bluebird Bio (BLUE) also has a competing gene therapy for sickle cell (Lyfgenia), so the pediatric label expansion by Casgevy directly pressures Bluebird's ability to differentiate on age eligibility.

Catching sickle cell patients at age 2 instead of 12 doesn't just expand the label — it expands the revenue ceiling for Vertex and CRISPR Therapeutics.

Who's exposed: Bluebird Bio (BLUE) is the most direct loser. Its own sickle cell therapy now faces a competitor with a broader label. Bluebird is already in a fragile financial position, and losing the pediatric differentiation angle tightens its commercial window further. Traditional standard-of-care players — hydroxyurea manufacturers and transfusion-dependent supply chains — face slow-burn displacement as gene therapy access widens.

What to watch next: Casgevy's list price is roughly $2.2 million per patient. The real commercial question is payer coverage for pediatric patients, specifically whether Medicaid programs (which cover a large share of sickle cell patients) will reimburse at that level. Any CMS or state Medicaid coverage decision is the next meaningful catalyst for VRTX and CRSP.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →